| Name | AZD2932 |
| Description | AZD2932 is a potent, multi-targeted kinase inhibitor of VEGFR2, PDGFβ, Flt-3, and c-Kit. |
| Kinase Assay | Kinase Assays : In vitro kinase IC50 values are measured using 33P filtration binding assay after 1 hour incubation of kinase, 33P-ATP, Ibrutinib, and substrate [0.2 mg/mL poly(EY)(4:1]. Assays are performed at Reaction Biology. |
| In vitro | In the C6 rat glioma model, oral administration of AZD2932 (12.5 or 50 mg/kg, b.i.d.) was able to inhibit tumor growth. Additionally, in xenografts with tumors not expressing PDGFβ, oral doses of AZD2932 (50 mg/kg, b.i.d.) succeeded in suppressing the growth of Calu-6 and LoVo tumors. |
| In vivo | AZD2932 effectively inhibits the phosphorylation of PDGFRα and PDGFRβ, demonstrating strong activity against a variety of receptors including VEGFR-2 (IC50=8 nM), PDGFRβ (IC50=4 nM), Flt-3 (IC50=7 nM), and c-Kit (IC50=9 nM). |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 82 mg/mL (183.2 mM)
H2O : < 1 mg/mL (insoluble or slightly soluble)
Ethanol : 5 mg/mL (11.17 mM), Heating is recommended.
|
| Keywords | Platelet-derived growth factor receptor | Inhibitor | VEGFR | c-Kit | Fms like tyrosine kinase 3 | Cluster of differentiation antigen 135 | Vascular endothelial growth factor receptor | FLT3 | SCFR | inhibit | PDGFR | AZD2932 | CD117 | AZD 2932 | AZD-2932 | CD135 |
| Inhibitors Related | Ribociclib | Gilteritinib | Nintedanib | Regorafenib monohydrate | Sorafenib | Pexidartinib | Regorafenib | Sorafenib tosylate | Lenvatinib mesylate | Imatinib | Pazopanib | Axitinib |
| Related Compound Libraries | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Tyrosine Kinase Inhibitor Library | Kinase Inhibitor Library | Anti-Ovarian Cancer Compound Library | Inhibitor Library | Anti-Cardiovascular Disease Compound Library | Anti-Prostate Cancer Compound Library | Bioactive Compounds Library Max | Anti-Liver Cancer Compound Library |
United States
